(SION) Sionna Therapeutics, Common - Overview
Stock: Galicaftor, Navocaftor, SION-109, SION-2851, SION-719
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 151% |
| Relative Tail Risk | -13.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.13 |
| Alpha | 88.20 |
| Character TTM | |
|---|---|
| Beta | 0.720 |
| Beta Downside | 1.697 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.36% |
| CAGR/Max DD | 1.46 |
Description: SION Sionna Therapeutics, Common January 17, 2026
Sionna Therapeutics (NASDAQ:SION) is a clinical-stage biopharma headquartered in Waltham, MA, that focuses exclusively on cystic fibrosis (CF) therapeutics. Its pipeline includes galicaftor (SION-2222, a TMD1-directed CFTR corrector) and navocaftor (SION-3067, a potentiator), both of which have completed Phase 2 trials, as well as early-stage candidates SION-109, SION-2851, SION-719 and SION-451 that are currently in Phase 1. The company was incorporated in 2019 (formerly Sling Therapeutics) and rebranded in July 2021.
Assumption: The Phase 2 data for galicaftor and navocaftor are positive enough to support progression to Phase 3, given the typical regulatory pathway for CF modulators. Uncertainty remains around the magnitude of clinical benefit relative to established competitors (e.g., Vertex’s Trikafta) and the timeline for FDA submission.
Key sector drivers: • The global CF drug market is projected to exceed $10 billion by 2028, driven by a growing diagnosed patient pool (~80,000 in the U.S.) and demand for next-generation modulators that address residual disease. • Biotech R&D spending has risen ~12 % YoY, increasing capital availability for companies with differentiated pipelines. • Cash burn rates for early-stage biotech firms average $30–40 million per quarter; SION’s latest 10-Q (Q3 2024) reported $35 million cash on hand, implying ~9-month runway without additional financing.
From a valuation perspective, the upside potential hinges on Sionna’s ability to demonstrate additive efficacy or safety advantages over existing CF therapies, which would justify premium pricing and market share capture. Conversely, a failure to differentiate could compress the valuation to a pure-play biotech multiple (~6-8× forward EV/EBITDA) given the high execution risk.
For a deeper, data-driven assessment of SION’s risk-adjusted upside, you may find the analyst tools on ValueRay useful for benchmarking against sector peers.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.18 > 0.02 and ΔFCF/TA 6.45 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.18 > 3% & CFO -61.5m > Net Income -70.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 25.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.5m) vs 12m ago 0.77% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -13.94 > 6 (EBITDA TTM -75.3m / Interest Expense TTM -5.46m) |
Altman Z'' -13.53
| A: 0.71 (Total Current Assets 252.3m - Total Current Liabilities 9.85m) / Total Assets 339.3m |
| B: -0.70 (Retained Earnings -235.9m / Total Assets 339.3m) |
| C: -0.28 (EBIT TTM -76.1m / Avg Total Assets 268.3m) |
| D: -13.38 (Book Value of Equity -235.4m / Total Liabilities 17.6m) |
| Altman-Z'' Score: -13.53 = D |
What is the price of SION shares?
Over the past week, the price has changed by -14.55%, over one month by -2.98%, over three months by +4.97% and over the past year by +100.61%.
Is SION a buy, sell or hold?
- StrongBuy: 3
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SION price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 44.9 | 24.2% |
| Analysts Target Price | 44.9 | 24.2% |
| ValueRay Target Price | 41.8 | 15.8% |
SION Fundamental Data Overview February 01, 2026
Revenue TTM = 0.0 USD
EBIT TTM = -76.1m USD
EBITDA TTM = -75.3m USD
Long Term Debt = 8.97m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.22m USD (from shortTermDebt, last quarter)
Debt = 8.97m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -41.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.65b USD (1.89b + Debt 8.97m - CCE 248.3m)
Interest Coverage Ratio = -13.94 (Ebit TTM -76.1m / Interest Expense TTM -5.46m)
EV/FCF = -26.84x (Enterprise Value 1.65b / FCF TTM -61.7m)
FCF Yield = -3.73% (FCF TTM -61.7m / Enterprise Value 1.65b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 247.0k) / Revenue TTM)
Tobins Q-Ratio = 4.88 (Enterprise Value 1.65b / Total Assets 339.3m)
Interest Expense / Debt = -60.91% (Interest Expense -5.46m / Debt 8.97m)
Taxrate = 21.0% (US default 21%)
NOPAT = -60.1m (EBIT -76.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 25.61 (Total Current Assets 252.3m / Total Current Liabilities 9.85m)
Debt / Equity = 0.03 (Debt 8.97m / totalStockholderEquity, last quarter 321.7m)
Debt / EBITDA = 0.56 (negative EBITDA) (Net Debt -41.9m / EBITDA -75.3m)
Debt / FCF = 0.68 (negative FCF - burning cash) (Net Debt -41.9m / FCF TTM -61.7m)
Total Stockholder Equity = 211.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.35% (Net Income -70.7m / Total Assets 339.3m)
RoE = -33.41% (Net Income TTM -70.7m / Total Stockholder Equity 211.5m)
RoCE = -34.53% (EBIT -76.1m / Capital Employed (Equity 211.5m + L.T.Debt 8.97m))
RoIC = -28.43% (negative operating profit) (NOPAT -60.1m / Invested Capital 211.5m)
WACC = 8.53% (E(1.89b)/V(1.90b) * Re(8.57%) + (debt cost/tax rate unavailable))
Discount Rate = 8.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 33.33%
Fair Price DCF = unknown (Cash Flow -61.7m)
EPS Correlation: 85.92 | EPS CAGR: 7348 % | SUE: 1.82 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.50 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=-2.14 | Chg30d=+0.019 | Revisions Net=-3 | Growth EPS=-5.2% | Growth Revenue=+0.0%